{"id":"https://genegraph.clinicalgenome.org/r/249245f7-1c3e-4faf-908a-160807f37dc6v1.1","type":"EvidenceStrengthAssertion","dc:description":"TAZ, historically known as G4.5, was first reported in relation to x-linked Barth syndrome in 1996 (Bione et al., PMID: 8630491). This disorder was formally characterized by Barth et al. in 1983 as an x-linked mitochondrial disease with the characteristic phenotypes of dilated cardiomyopathy, skeletal myopathy, and neutropenia (PMID: 6142097). Barth syndrome can prenatally present as fetal DCM, hydrops, severe fetal decompensation necessitating emergency delivery and stillbirth, as seen in molecularly confirmed cases (PMID: 20812380). Additionally male miscarriages, stillbirth have been noted in multiple Barth syndrome families (PMIDs: 20812380, 27124939, 10484795, 28183324). Over 100 variants, mostly premature termination or splice-altering with some missense, have been reported in humans to date. Evidence supporting this gene-disease relationship includes case-level data, segregation data, and experimental data.\nVariants in this gene have been reported in at least eleven probands in four publications (PMIDs: 8630491, 16906470, 10484795, 23031367) and have segregated with disease in three of those families. This combination of significant segregation (Summed LOD score: 9.22) and high frequency of predicted/proven null variants reaches the maximum score for genetic evidence with more evidence available in the literature. The mechanism for disease is hemizygous loss-of-function, with loss of tafazzin enzymatic activity as a phospholipid acyltransferase affecting the maturation of the protein cardiolipin. Cardiolipin is an essential part of the mitochondrial membrane for mitochondrial morphology and function, as well as having other functions in cardiac function, apoptosis, autophagy, cell cycle regulation, and Fe-S cluster biosynthesis (PMID: 23200781). Dysregulation causes a cascade of effects including respiratory chain dysfunction, extensive mitochondrial aberrations, ultrastructural muscle damage, and destabilized super-complexes and metabolic complexes causing the observed phenotypes in Barth syndrome.\nThis gene-disease association is supported by tafazzin and cardiolipin's biochemical functions and altered tafazzin enzymatic activity in patient fibroblasts. Several studies have been performed on \"knockdown\" mouse models expressing siRNAs to inhibit TAZ mRNA production when fed varying amounts of doxycycline. The results range in severity from premature lethality due to cardiomyopathy to relatively minor skeletal and cardiac abnormalities, recapitulating the phenotypes observed in human probands. Finally, a rescue performed on the same mice via AAV vectors with human TAZ cDNA restored cardiac and skeletal function of the mice to near WT levels while also improving the mitochondial abnormalities observed.\nIn summary, TAZ is definitively associated with x-linked Barth syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/249245f7-1c3e-4faf-908a-160807f37dc6","GCISnapshot":"https://genegraph.clinicalgenome.org/r/1629e6ab-9749-4949-bf54-fe1addf4dcfd","calculatedEvidenceStrength":"Definitive","changes":[{"id":"cg:otherTextChange"},{"id":"cg:summaryChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/1629e6ab-9749-4949-bf54-fe1addf4dcfd_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10097","date":"2022-12-08T16:58:33.232Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/1629e6ab-9749-4949-bf54-fe1addf4dcfd_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10097","date":"2021-02-12T17:00:00.000Z","role":"Approver"},{"agent":"https://genegraph.clinicalgenome.org/agent/10106","role":"SecondaryContributor"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1629e6ab-9749-4949-bf54-fe1addf4dcfd_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1629e6ab-9749-4949-bf54-fe1addf4dcfd_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e69be104-f084-4a10-a877-e16a28ba12fd_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough info","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23031367","rdfs:label":"RO","estimatedLodScore":1.2,"family":{"id":"https://genegraph.clinicalgenome.org/r/e69be104-f084-4a10-a877-e16a28ba12fd","type":"Family","rdfs:label":"RO","member":{"id":"https://genegraph.clinicalgenome.org/r/4c2e28fa-d914-40b5-ab3d-f6ee08abf03e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23031367","rdfs:label":"ROIII-2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":51,"allele":{"id":"https://genegraph.clinicalgenome.org/r/9dd93ac5-eb96-41e0-821d-7d217b496922","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000116.5(TAZ):c.583G>T (p.Gly195Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/559336"}},"detectionMethod":"DNA was extracted from salavia and buccal swabs. DNA sequencing for all 11 exons of the TAZ gene was performed via PCR amplification and direct sequencing. Once the mutation was located, site-specific DNA sequencing was used on four unaffected family members to confirm segregation.","phenotypeFreeText":"Left ventricular enlargement, Septal and apical hypokinesis","phenotypes":["obo:HP_0001640","obo:HP_0003803","obo:HP_0012764","obo:HP_0001270","obo:HP_0008180","obo:HP_0000218","obo:HP_0031195","obo:HP_0009046","obo:HP_0003458","obo:HP_0001252","obo:HP_0012664","obo:HP_0011807","obo:HP_0012432","obo:HP_0003691","obo:HP_0001324","obo:HP_0000486","obo:HP_0030682","obo:HP_0001533","obo:HP_0001882","obo:HP_0002359","obo:HP_0025169","obo:HP_0003700","obo:HP_0003551","obo:HP_0001875","obo:HP_0003323","obo:HP_0001635","obo:HP_0001382"],"previousTesting":true,"previousTestingDescription":"Normal lipid profile [total cholesterol 147mg/dL, triglycerides 39 mg/dL, HDL cholesterol 56 mg/dL, LDL cholesterol 83 mg/dL], normal total and free carnitine levels, normal acylcarnitine profile, and normal urine organic acids with no elevation of 3-methylglutaconic acid; DNA testing for myotonic dystophy types 1 and 2 revealed normal alleles; Now maintained on digoxin, beta-blocker and anti-coagulation treatments","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/2cbc2a67-59ca-4f5e-89b1-b14fc86b4f6a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23031367","allele":{"id":"https://genegraph.clinicalgenome.org/r/9dd93ac5-eb96-41e0-821d-7d217b496922"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0001875","obo:HP_0001640","obo:HP_0012664","obo:HP_0001635","obo:HP_0001324","obo:HP_0001252"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/4c2e28fa-d914-40b5-ab3d-f6ee08abf03e"}},{"id":"https://genegraph.clinicalgenome.org/r/d44d7425-6088-4825-aa4c-27ce9a6aff5a_proband_segregation","type":"FamilyCosegregation","dc:description":"Enough segregations to count","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8630491","rdfs:label":"BI3","estimatedLodScore":1.2,"family":{"id":"https://genegraph.clinicalgenome.org/r/d44d7425-6088-4825-aa4c-27ce9a6aff5a","type":"Family","rdfs:label":"BI3","member":{"id":"https://genegraph.clinicalgenome.org/r/265638ff-b16c-485b-91f6-d32a5febf7f1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8630491","rdfs:label":"BI3GW","allele":{"id":"https://genegraph.clinicalgenome.org/r/d466b710-5ef6-46ef-a10a-fc53f1e6edd2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000116.5(TAZ):c.239-1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11100"}},"detectionMethod":"Five genes noted to have high heart and skeletal muscle expression were sequenced and ORFs created. After PCR amplification and direct sequencing of the TAZ gene (G4.5.), each family was seen to have a unique variant that segregated with the disease.","phenotypes":["obo:HP_0003756","obo:HP_0001875","obo:HP_0001644"],"previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/568bc7e7-9c5f-4c7d-8bec-543f8140e912_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8630491","allele":{"id":"https://genegraph.clinicalgenome.org/r/d466b710-5ef6-46ef-a10a-fc53f1e6edd2"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}}},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":3,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0001644","obo:HP_0001875","obo:HP_0003756"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/265638ff-b16c-485b-91f6-d32a5febf7f1"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/3fabf539-38a7-4c84-b59f-15fd8bd50e20_proband_segregation","type":"FamilyCosegregation","dc:description":"Enough evidence to count","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8630491","rdfs:label":"BI4","estimatedLodScore":4.21,"family":{"id":"https://genegraph.clinicalgenome.org/r/3fabf539-38a7-4c84-b59f-15fd8bd50e20","type":"Family","rdfs:label":"BI4","member":{"id":"https://genegraph.clinicalgenome.org/r/c931a46e-2e7c-4bd5-af88-4a27eb3dc7d7","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8630491","rdfs:label":"BI4OAT","ageType":"AgeAtDeath","ageUnit":"Years","ageValue":10,"allele":{"id":"https://genegraph.clinicalgenome.org/r/2bbafea5-a597-4ea0-acea-2a932871e6c2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"TAZ, 1-BP INS, NT868","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11103"}},"detectionMethod":"DNA was extracted from blood samples. PCR marker studies and restriction digest was performed with subsequent linkage analysis to confirm the localization to Xq28. In this study, five genes noted to have high heart and skeletal muscle expression were sequenced and ORFs created. After PCR amplification and direct sequencing of the TAZ gene (G4.5.), each family was seen to have a unique variant that segregated with the disease.","phenotypeFreeText":"Pulmonary venous congestion, Apical thrombus","phenotypes":["obo:HP_0007107","obo:HP_0001488","obo:HP_0020049","obo:HP_0001583","obo:HP_0001254","obo:HP_0001270","obo:HP_0000666","obo:HP_0002039","obo:HP_0001776","obo:HP_0000767","obo:HP_0000634","obo:HP_0002522","obo:HP_0003756","obo:HP_0001324","obo:HP_0001510","obo:HP_0007126","obo:HP_0000582","obo:HP_0001640","obo:HP_0002018","obo:HP_0003438","obo:HP_0002119","obo:HP_0001290","obo:HP_0000762","obo:HP_0012311","obo:HP_0040160","obo:HP_0001644","obo:HP_0002094","obo:HP_0001875","obo:HP_0009058","obo:HP_0003458","obo:HP_0001635","obo:HP_0430025","obo:HP_0000347","obo:HP_0002007"],"previousTesting":true,"previousTestingDescription":"Born at term w/ weight of 3,450 grams; Normal speech, hearing, intelligence at 18 months; Normal median NCV (46 m/s) w/ slow peroneal NCV (33 m/s)","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/de2a70f8-e6f8-4f86-9286-182fea4b4f61_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8630491","allele":{"id":"https://genegraph.clinicalgenome.org/r/2bbafea5-a597-4ea0-acea-2a932871e6c2"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":6,"phenotypes":["obo:HP_0001510","obo:HP_0001875","obo:HP_0001644","obo:HP_0003756"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/c931a46e-2e7c-4bd5-af88-4a27eb3dc7d7"},"publishedLodScore":2.78,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/56179875-b5a1-441b-a38f-4ef903229ec1_proband_segregation","type":"FamilyCosegregation","dc:description":"Enough segregations for valid evidence. DXS305 multipoint LOD score.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8630491","rdfs:label":"BI1","estimatedLodScore":2.71,"family":{"id":"https://genegraph.clinicalgenome.org/r/56179875-b5a1-441b-a38f-4ef903229ec1","type":"Family","rdfs:label":"BI1","member":{"id":"https://genegraph.clinicalgenome.org/r/347e6762-3b78-4cc4-afc7-cb7cfc38b438","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8630491","rdfs:label":"BI1V-12","ageType":"AgeAtDeath","ageUnit":"Months","ageValue":15,"allele":{"id":"https://genegraph.clinicalgenome.org/r/5e4d31da-24e6-4522-9cb1-79bea65a6e0a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000116.5(TAZ):c.153C>G (p.Tyr51Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA255717"}},"detectionMethod":"The family was investigated for linkage analysis via chromosomal DNA extraction from white blood cells and fibroblasts. These were tested with 28 x-chromosomal probes for heterozygosity in carriers, leading to an identified area near Xq28. The 30 genes in this region were identified and five were noted to have high heart and skeletal muscle expression. All five were sequenced and ORFs created. After PCR amplification and direct sequencing of the TAZ gene (G4.5.), each family was seen to have a unique variant that segregated with the disease.","phenotypeFreeText":"Birthweight 2.5 kg, Spherical mitochondria","phenotypes":["obo:HP_0001644","obo:HP_0001875","obo:HP_0006670","obo:HP_0001259","obo:HP_0001640","obo:HP_0002045","obo:HP_0003756","obo:HP_0001284","obo:HP_0001695","obo:HP_0001942","obo:HP_0003202","obo:HP_0002789","obo:HP_0033113","obo:HP_0002069","obo:HP_0012240","obo:HP_0001635","obo:HP_0002643","obo:HP_0004902","obo:HP_0001880","obo:HP_0001270"],"previousTesting":true,"previousTestingDescription":"10,200/mm^3 leukocytes in blood compared to 8% neutrophils, Blood glucose 0.5 mM at death, Abnormal ring-shaped mitochondrial cristae, Electron-dense central inclusions","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/f555f525-a9b0-4d63-86e8-0cc2d4d4ea6f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8630491","allele":{"id":"https://genegraph.clinicalgenome.org/r/5e4d31da-24e6-4522-9cb1-79bea65a6e0a"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}}},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":6,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0001875","obo:HP_0001644","obo:HP_0003756","obo:HP_0001635"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/347e6762-3b78-4cc4-afc7-cb7cfc38b438"},"publishedLodScore":5.24,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/74ccf587-68ea-4209-b8a8-95a60afefbcd","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/74ccf587-68ea-4209-b8a8-95a60afefbcd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10484795","allele":{"id":"https://genegraph.clinicalgenome.org/r/91371fc0-6d14-47f2-a67d-3c2a76012fea","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.154411852dup (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1139655406"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/3e93dd9f-cf4a-4ec9-acdc-a3a061907e82","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3e93dd9f-cf4a-4ec9-acdc-a3a061907e82_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16906470","allele":{"id":"https://genegraph.clinicalgenome.org/r/698f221f-7a32-4e80-a307-cb0f55c13cf4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000116.5(TAZ):c.541+1G>A (p.=)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA415183775"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/8da33d62-62f7-4a30-a130-5c6cf149ac77","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8da33d62-62f7-4a30-a130-5c6cf149ac77_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8630491","allele":{"id":"https://genegraph.clinicalgenome.org/r/06acd21d-f926-45db-aedb-9fe25c4d7959","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000116.5(TAZ):c.239-1G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11102"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/aedcca63-944f-4de1-b1bf-7bed3039ec94","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aedcca63-944f-4de1-b1bf-7bed3039ec94_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10484795","allele":{"id":"https://genegraph.clinicalgenome.org/r/c4c98790-5e6f-437b-a6c9-56220f3d0ae3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000116.5(TAZ):c.548T>G (p.Val183Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA415183843"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/171111f0-7221-4911-988a-87fdb056ba2e","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/171111f0-7221-4911-988a-87fdb056ba2e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10484795","allele":{"id":"https://genegraph.clinicalgenome.org/r/01f397f2-9475-4832-a7f9-5c70e0801d65","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000116.5(TAZ):c.589G>A (p.Gly197Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA255719"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/2cbc2a67-59ca-4f5e-89b1-b14fc86b4f6a","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2cbc2a67-59ca-4f5e-89b1-b14fc86b4f6a_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/f0fa9e05-5859-426d-9d81-fb3f128eb22e","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f0fa9e05-5859-426d-9d81-fb3f128eb22e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10484795","allele":{"id":"https://genegraph.clinicalgenome.org/r/50e8932e-c457-4c82-98fc-bd40fc83ad4b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000116.5(TAZ):c.629T>G (p.Leu210Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA415184340"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/de2a70f8-e6f8-4f86-9286-182fea4b4f61","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/de2a70f8-e6f8-4f86-9286-182fea4b4f61_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/f555f525-a9b0-4d63-86e8-0cc2d4d4ea6f","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f555f525-a9b0-4d63-86e8-0cc2d4d4ea6f_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/38e0ec93-5622-445c-805b-040d962520b6","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/38e0ec93-5622-445c-805b-040d962520b6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16906470","allele":{"id":"https://genegraph.clinicalgenome.org/r/01f397f2-9475-4832-a7f9-5c70e0801d65"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/e7f4c23a-1373-41d6-a97c-3635e2d59524","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e7f4c23a-1373-41d6-a97c-3635e2d59524_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10484795","allele":{"id":"https://genegraph.clinicalgenome.org/r/01f397f2-9475-4832-a7f9-5c70e0801d65"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/568bc7e7-9c5f-4c7d-8bec-543f8140e912","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/568bc7e7-9c5f-4c7d-8bec-543f8140e912_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/1629e6ab-9749-4949-bf54-fe1addf4dcfd_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1629e6ab-9749-4949-bf54-fe1addf4dcfd_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e1454fa5-1506-4df3-9561-98dd36b8ee2c","type":"EvidenceLine","dc:description":"Although the biochemical evidence supporting this pathogenicity is somewhat indirect, the functional studies and evidence that these specific interactions and proteins leads to Barth syndrome phenotypes are substantial. The characteristic MLCL/CL ratio alteration and the 3-methylglutaric aciduria demonstrates how this biochemical function reflects the phenotype. Therefore, this earns 1.0 points.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/da62eff9-e89b-4d1f-96fd-7d41d0b24465","type":"Finding","dc:description":"This specific acyltransferase enzyme activity is crucial to one particlar protein, cardiolipin. This protein is synthesized de novo from phosphatidic acid via the cytidine-5สน-diphosphate-1,2-diacyl-sn-glycerol pathway, but also requires tafazzin to fully mature itself into the form typically found in mitochondrial membranes. Mature cardiolipin is essential in the mitochondrial membrane for mitochondrial morphology and function, as well as having other functions in cardiac function, apoptosis, autophagy, cell cycle regulation, and Fe-S cluster biosynthesis (PMID: 23200781). Loss of TAZ function causes a resulting alteration of cardiolipin, causing a cascade of effects including respiratory chain dysfunction, extensive mitochondrial aberrations, ultrastructural muscle damage, and destabilized super-complexes and metabolic complexes. All of these pathways could easily cause the phenotypes observed in Barth syndrome, including the cardiomyopathy, skeletal myopathy, and failure to thrive.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17082194","rdfs:label":"Tafazzin Cardiolipin Interaction","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/1629e6ab-9749-4949-bf54-fe1addf4dcfd_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/214ab9a9-8406-4c0a-9c56-4d70d54a3258","type":"EvidenceLine","dc:description":"This evidence uses fibroblasts from a variety of patients and variants to demonstrate the characteristic altered tafazzin activity using the MLCL/CL ratio. Expression of the WT and potential active splice variant brought the ratio significantly closer to the control value, indicating a partial rescue of the altered phenotype. Therefore, this evidence earns default points.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c110678a-31d8-4330-9c2f-3383a7f4b975","type":"FunctionalAlteration","dc:description":"Several relevant tafazzin slice variants (full transcript, -ex5, and -ex7) were expressed in human BTHS fibroblasts and the MLCL/CL ratio was compared to age-matched controls and the previous results from the fibroblasts themselves. This ratio is important as the amount of cardiolipin (CL) conversion by tafazzin is crucial to the disease progress and observable phenotypes. Overall, the ratio observed in fibroblasts alone was significantly higher than controls (~1.1, reference 0.12). The expression of tafazzin splice variants did rescue some of the ratio, although only the preumed active variant lacking exon 5 showed significant decrease of the ratio (~0.5).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19619503","rdfs:label":"TAZ Function in Patient Fibroblasts"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/1629e6ab-9749-4949-bf54-fe1addf4dcfd_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/15f1ff58-0479-4729-865b-4842d38f10f9","type":"EvidenceLine","dc:description":"This rescue affects many of the essential phenotypes of Barth syndrome, including the cardiac dysfunction, muscle weakness, increased fatiguability, and the morphological abnormalities in mitochondria. As expression of the WT cDNA for tafazzin significantly improves all of these functions, this provides significant evidence towards its pathogenicity. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/33711ae9-485b-4aee-990b-7c8181491812","type":"Finding","dc:description":"Gene expression assays confirmed transcription of TAZ that slightly varied by vector and injection age, with both the Des and 5' TAZ promoters being significantly more effective in the cardiac tissue. Western blotting demonstrated the most effective protein reduction on neonates, with the rescue increasing the amount compared to controls. Exercise studies demonstrated improvement in all three groups compared to the TAZKD group in reduced resting times, increased average fast movement times, and total distance traveled. Cardiac function also showed improvement, with a universal increase in ejection fraction and heart/body weight ratios closer to WT. Force mechanics evaluations demonstrated a significant improvement in fatiguability over the TAZKD mice. Mitochondrial structural defects were significantly improved, with increased organization, cristae organization and structure, and total area. Mitochondrial health was also confirmed to improve, with cardiac respiration showing closer to WT consumption rates in State 3/4u.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30070157","rdfs:label":"TAZKD AAV-Mediated Rescue","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/beff5de5-4cff-4b9c-ae5c-8e2f522487da","type":"EvidenceLine","dc:description":"Although the mice presented in these models do recapitulate many of the characteristic phenotypes of Barth syndrome, such as cardiac dysfunction and muscle weakness/atrophy, the methodology of indirectly knocking down TAZ via doxycycline siRNA release yields an uncertain clinical picture. Doxycycline itself can have effects on the phenotypic spectrum, and the large percentage of mRNA knockdown does not necessarily reflect the protein levels in the observed mice. Overall, with both positive and negative aspects, this model earns default points.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/054a8e63-67f3-42aa-a3b9-c4eaa5a718ff","type":"Finding","dc:description":"PMID 21091282: To induce snRNA expression in vivo, doxycycline chow was fed to breeding pairs and to the pups for the remainder of the experiments. Quantitative RT-PCR showed a significant reduction of TAZ mRNA levels in all tissues tested at 2 months (ranging from 71 +/- 8.6% in liver to 94.7 +/- 0.3% in tibialis anterior muscle. TAZKD in cardiac tissue led to an increase in the MLCL/CL ratio at 2 months of age, similar to that found in human probands. Mitochondrial abnormalities were also observed in these mutant mice, specifically abnormal size and disruption of the cristae. Impaired skeletal muscle contractile properties and cardiac dysfunction were also notable, in the mutant mice, reflecting similar abnormalities observed in human probands. PMID 23130124: Doxycycline was introduced in the drinking water of bredding couples, with a stop and start for males to prevent infertility. This method resulted in a much larger influx of doxycycline and a corresponding decrease in mRNA expression (>90-95% knockdown in all tested tissues, 80% reduction in embryos by three days). However, this method also caused complete embryonic lethality due to severe diastolic dysfunction associated with left ventricular noncompaction. Investigation revealed that these mice harbored significantly modified mitochondial cristae and had delayed cardiomyocyte differentiation.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21091282","rdfs:label":"TAZKD Murine Model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":5397,"specifiedBy":"GeneValidityCriteria7","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/KKz5d6rH1c0","type":"GeneValidityProposition","disease":"obo:MONDO_0010543","gene":"hgnc:11577","modeOfInheritance":"obo:HP_0001417"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_1629e6ab-9749-4949-bf54-fe1addf4dcfd-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}